‘Made in Chandigarh’ technology to bring down prices of insulin and Hepatitis B vaccine
AdvertisementIf everything at the
Presently India has to depend on patented technology of the foreign countries to produce insulin, streptokinase and hepatitis B etc. With 66 million diabetics and 40 million hepatitis B patients in the country, this will be a major reliever for many.
Pichia is the vector that is currently used in insulin.
"Because Pichia is patented, Indian biotech companies have to pay the inventor, which adds to the cost of the vaccine. Thus, we felt the need to develop new expression systems," Dr
Pichia vector is generally licensed for commercial research for $50,000 with annual maintenance fee of $5000 to $30,000. In case the product is commercialized, the fee is $75,000 plus royalty ranging between 3% and 5%.
The present cost of hepatitis B vaccine in India ranges between Rs 45 (
"So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast. Once the production is scaled up, the production cost is estimated to be around Re 1 per dose, while the lowest production cost reported for Pichia-based system is Rs. 4 per dose and the lowest
Popular on BI
- A top AI researcher reportedly left Google for OpenAI after sharing concerns the company was training Bard on ChatGPT data
- An AI researcher who has been warning about the technology for over 20 years says we should 'shut it all down,' and issue an 'indefinite and worldwide' ban
- What is an indictment? What it means for someone to be indicted by a grand jury and why Trump was charged
- India reports 3,824 new Covid cases
- 77% of young Indians now spend the most on phones, apparels
- Global Pharma recalls 50,000 tubes of contaminated eye drops in US: USFDA
- Former India cricketer Salim Durani passes away aged 88; PM Narendra Modi, Ravi Shastri lead tributes
- India successfully achieves autonomous landing of Space vehicle